NCT06878976 Phase 3 Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder Study sponsor: Axsome Therapeutics, Inc. · AXSM
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-12 Estimated
Enrollment · participants 236 Estimated
Source updated 2026-08-11 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-08-11 · 3 fields changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Long-term Safety
+ Updated value measure: Time from randomization to relapse of binge eating in the RW segment
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count Recorded edit − Previous value count: 300; type: ESTIMATED
+ Updated value count: 236; type: ESTIMATED
Primary completion date Recorded edit Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial